Vaccibody AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of local… Read more
Vaccibody AS (5VB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.061x
Based on the latest financial reports, Vaccibody AS (5VB) has a cash flow conversion efficiency ratio of -0.061x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.02 Million) by net assets (€99.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vaccibody AS - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Vaccibody AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vaccibody AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaccibody AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Banestes S.A - Banco do Estado do Espírito Santo
SA:BEES3
|
-1.747x |
|
Global InterConnection Group Limited
F:9OD
|
N/A |
|
Skyharbour Resources Ltd
OTCQX:SYHBF
|
0.053x |
|
Go Hub Capital Berhad
KLSE:0311
|
0.017x |
|
China Everbright Greentech Limited
F:CK7
|
-0.006x |
|
InspireMD Inc
NASDAQ:NSPR
|
-0.135x |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
-0.038x |
|
Index Living Mall Public Company Limited
BK:ILM
|
0.084x |
Annual Cash Flow Conversion Efficiency for Vaccibody AS (2018–2024)
The table below shows the annual cash flow conversion efficiency of Vaccibody AS from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €136.21 Million | €-51.22 Million | -0.376x | +33.35% |
| 2023-12-31 | €171.26 Million | €-96.62 Million | -0.564x | -328.11% |
| 2022-12-31 | €157.02 Million | €-20.69 Million | -0.132x | -2314.20% |
| 2021-12-31 | €194.06 Million | €1.16 Million | 0.006x | -99.41% |
| 2020-12-31 | €178.85 Million | €180.27 Million | 1.008x | +405.45% |
| 2019-12-31 | €30.44 Million | €-10.04 Million | -0.330x | +30.75% |
| 2018-12-31 | €15.12 Million | €-7.21 Million | -0.476x | -- |